Natdac
indicated to manage hepatitis c to mitigate viral infection.
Strengths: 60mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Epclusa
- Therapeutic class
Direct-Acting Antiviral
- Pharmacological class
HCV Protease/Polymerase Inhibitor
- Contraindications
hypersensitivity to active components
- Minor side effects
fatigue; headache; nausea
- Moderate side effects
insomnia; dizziness; diarrhoea
- Dosage forms
Tablet
- Administration route
Oral use
- Patient summary
indicated to manage hepatitis c to mitigate viral infection.
- Prescription status
POM
- Manufacturer
Natco Pharma
- Onset Time
1–2 weeks
- Duration
12–24 weeks
- Storage instructions
Store in original packaging.
- Drug interactions
amiodarone; rifampicin; st. john's wort
- Age restrictions
For adults.
- Pregnancy and breastfeeding
Pregnancy: Not recommended. Breastfeeding: Not recommended.
Precautions and warnings
monitor for hepatitis b reactivation; frequent monitoring of liver function; no alcohol consumption
Serious side effects
hepatitis b reactivation — requires immediate medical attention; severe bradycardia — requires immediate medical attention
Mechanism of action
This combination therapy targets the HCV NS5A and NS5B proteins, inhibiting viral replication through multiple pathways. This multi-target approach is essential for achieving a sustained virological response.
Natdac
indicated to manage hepatitis c to mitigate viral infection.
Editorial Notes
- Active ingredient(s): Tenofovir Disoproxil, Daclatasvir, Sofosbuvir
- Listed indication(s): Chronic Hepatitis C
Available option
- 28 tablets - 60 mg1510-60-mg-17919